Literature DB >> 29122410

Non-compliance with IDSA guidelines for patients presenting with methicillin-susceptible Staphylococcus aureus prosthetic joint infection is a risk factor for treatment failure.

A Bouaziz1, I Uçkay2, S Lustig3, A Boibieux1, D Lew2, P Hoffmeyer2, P Neyret4, C Chidiac5, T Ferry6.   

Abstract

OBJECTIVE: The long-term impact of treatment strategies proposed by the IDSA guidelines for patients presenting with methicillin-susceptible S. aureus (MSSA) prosthetic joint infection (PJI) is not well-known. PATIENTS AND METHODS: Retrospective (2000-2010) cohort study including patients presenting with MSSA hip or knee PJI. A univariate Cox analysis was performed to determine if the non-compliance with IDSA surgical guidelines was a risk factor for treatment failure.
RESULTS: Eighty-nine patients with a mean follow-up of 2.8 years were included. Non-compliance with IDSA surgical guidelines was associated with treatment failure (hazard ratio 2.157; 95% CI [1.022-4.7]). The American Society of Anesthesiologists score, inadequate antimicrobial therapy, and a rifampicin-based regimen did not significantly influence patient outcome.
CONCLUSION: Based on the IDSA guidelines, if a patient presenting with MSSA PJI is not eligible for implant retention, complete implant removal is needed to limit treatment failure.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Guidelines; Infections de prothèses articulaires; MSSA; Prosthetic joint infections; Recommandations; SASM

Mesh:

Substances:

Year:  2017        PMID: 29122410     DOI: 10.1016/j.medmal.2017.09.016

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  6 in total

1.  Arthroscopic "Debridement and Implant Retention" With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection.

Authors:  Tristan Ferry; Cécile Batailler; Aubin Souche; Cara Cassino; Christian Chidiac; Thomas Perpoint; Claire le Corvaisier; Jérôme Josse; Romain Gaillard; Julien Roger; Camille Kolenda; Sébastien Lustig; Frédéric Laurent
Journal:  Front Med (Lausanne)       Date:  2021-05-14

2.  Salvage Debridement, Antibiotics and Implant Retention ("DAIR") With Local Injection of a Selected Cocktail of Bacteriophages: Is It an Option for an Elderly Patient With Relapsing Staphylococcus aureus Prosthetic-Joint Infection?

Authors:  Tristan Ferry; Gilles Leboucher; Cindy Fevre; Yannick Herry; Anne Conrad; Jérôme Josse; Cécile Batailler; Christian Chidiac; Mathieu Medina; S Lustig; Frédéric Laurent
Journal:  Open Forum Infect Dis       Date:  2018-10-24       Impact factor: 3.835

3.  Bone and Joint Infection Involving Corynebacterium spp.: From Clinical Features to Pathophysiological Pathways.

Authors:  Pierre Chauvelot; Tristan Ferry; Virginie Tafani; Alan Diot; Jason Tasse; Anne Conrad; Christian Chidiac; Evelyne Braun; Sébastien Lustig; Frédéric Laurent; Florent Valour
Journal:  Front Med (Lausanne)       Date:  2021-01-21

4.  Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified?

Authors:  Nora Renz; Andrej Trampuz; Werner Zimmerli
Journal:  Antibiotics (Basel)       Date:  2021-02-05

Review 5.  Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis.

Authors:  H Scheper; L M Gerritsen; B G Pijls; S A Van Asten; L G Visser; M G J De Boer
Journal:  Open Forum Infect Dis       Date:  2021-07-01       Impact factor: 3.835

6.  Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France.

Authors:  Matteo Cerioli; Cécile Batailler; Anne Conrad; Sandrine Roux; Thomas Perpoint; Agathe Becker; Claire Triffault-Fillit; Sebastien Lustig; Michel-Henri Fessy; Frederic Laurent; Florent Valour; Christian Chidiac; Tristan Ferry
Journal:  Front Med (Lausanne)       Date:  2020-10-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.